Katherine Esposito

Glucagon-like peptide 1 receptor agonist for peripheral artery disease: Is it time to proceed?

Islet Autoantibodies in Adult With Pituitary and Ovarian Autoimmunity: Implications for Type 1 Diabetes Screening.

Ethanol ablation of cystic thyroid nodules: institutional experience with one year follow-up.

GLP1-1RAs improve walking distance and reduce amputation in people with type 2 diabetes and peripheral artery disease: A systematic review and meta-analysis of randomised controlled trials and cohort studies.

Liraglutide improves peripheral perfusion and markers of angiogenesis and inflammation in people with type 2 diabetes and peripheral artery disease: An 18-month follow-up of a randomized clinical trial.

Association of semaglutide with less limb events in people with type 2 diabetes and peripheral artery disease or foot ulcers: An observational study comparing matched cohorts.

Effect of SGLT-2 Inhibitors Versus DPP-4 Inhibitors on Peripheral Artery Disease Risk Among People With Type 2 Diabetes: A 48-Month Prospective Study.

Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.

Semaglutide cuts kidney risk in obesity.

The therapeutic efficacy of continuous glucose monitoring in diabetes: an updated meta-analysis with meta-regression.

Exploring Insulin Resistance in Adults With Type 1 Diabetes: The Role of the Estimated Glucose Disposal Rate and the Triglyceride Glucose Index.

The Glycemia Risk Index (GRI) as a Biomarker for Subclinical Endothelial Dysfunction in Type 1 Diabetes: A Cross-Sectional Study.

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.

Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.

Diabetic kidney disease: The fourth pharmacological pillar may be semaglutide.

Glucose control during breakthrough SARS-CoV-2 infections in vaccinated patients with type 1 diabetes

Correction: An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes

Correction: An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes.

Pleiotropic effects of GLP-1 receptor agonists on peripheral artery disease: Is there any hope?

An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes

An updated algorithm for an effective choice of continuous glucose monitoring for people with insulin-treated diabetes.

Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring.

Spot-light on microbiota in obesity and cancer

Teleassistance for Patients With Type 1 Diabetes During the COVID-19 Pandemic: Results of a Pilot Study.

Mediterranean diet in type 2 diabetes: An updated overview of pharmacological activities of cardiometabolic and reproductive outcomes

Sexual dysfunctions and short-term glucose variability in young men with type 1 diabetes.

Maternal and Fetal Outcomes in Women with Diabetes in Pregnancy Treated before and after the Introduction of a Standardized Multidisciplinary Management Protocol.

Alterations in the Levels of Circulating and Endothelial Progenitor Cells Levels in Young Adults with Type 1 Diabetes: A 2-Year Follow-Up from the Observational METRO Study.

Sexual dysfunctions in young women with type 1 diabetes and high glucose variability: findings from the METRO study.